Neutrophil in a field of blood cells
(
NCI)
by Ross Bonander
Neulasta (pegfilgrastim), administered subcutaneously, is a man-made drug that mimics the work of glycoproteins in the body known as colony-stimulating factors, which help promote the growth and proliferation of blood cells. Neulasta is given in order to encourage the growth of white blood cells known as neutrophils.
Neulasta is very similar to the colony-stimulating factor Neupogen (filgrastim): In Neulasta, filgrastim is attached to a molecule known as polyethylene glycol (known as PEG, thus the Neulasta name, pegfilgrastim). By attaching PEG to filgrastim, the drug can remain in the body longer, be given less often, while achieving the same result
Drug profile
- Class: Colony-stimulating factor
- Treatment type: Symptom management
- US approval: 2002
- Synonyms: G-CSF
- FDA Use-in-Pregnancy Rating: Category C
What Neulasta is effective for and why
Neulasta's primary indication is in the treatment of chemotherapy-induced febrile neutropenia.
Neulasta side effects: Overview
Allergic reactions to Neulasta have been reported, including hives, breathing difficulties, and swelling of the area around the face and throat. These are serious side effects and require immediate emergency attention.
Other side effects of Neulasta include dizziness, bruising or redness at the injection site, signs of infection including fever, sore throat, appetite loss, flu symptoms, and nausea or vomiting. Less serious side effects include bone pain, and pain in the arms and legs.
Sources
Significant studies relating to Neulasta
